LncRNA and circRNA in Patients with Non-Alcoholic Fatty Liver Disease: A Systematic Review DOI Creative Commons
Qingmin Zeng, Changhai Liu, Dongbo Wu

et al.

Biomolecules, Journal Year: 2023, Volume and Issue: 13(3), P. 560 - 560

Published: March 20, 2023

Non-alcoholic fatty liver disease (NAFLD) is currently the most common cause of chronic worldwide. Early identification and prompt treatment are critical to optimize patient management improve long-term prognosis. Long non-coding RNA (lncRNA) circular (circRNA) recently emerging RNAs, highly stable easily detected in circulation, representing a promising non-invasive approach for predicting NAFLD. A literature search Pubmed, Embase, Web Science, Cochrane Library databases was performed 36 eligible studies were retrieved, including 18 on NAFLD, 13 nonalcoholic steatohepatitis (NASH), 11 fibrosis and/or cirrhosis. Dynamic changes lncRNA expression associated with occurrence progression among which NEAT1, MEG3, MALAT1 exhibited great potential as biomarkers Moreover, mitochondria-located circRNA SCAR can drive metaflammation its inhibition might be therapeutic target NASH. In this systematic review, we highlight lncRNA/circRNA early diagnosis assessment To further verify their clinical value, large-cohort incorporating both tissue blood should conducted. Additionally, detailed functional mechanisms will essential elucidating roles diagnosing treating NASH, fibrosis.

Language: Английский

AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma DOI Open Access
Amit G. Singal, Josep M. Llovet, Mark Yarchoan

et al.

Hepatology, Journal Year: 2023, Volume and Issue: 78(6), P. 1922 - 1965

Published: May 18, 2023

Singal, Amit G.; Llovet, Josep M.; Yarchoan, Mark; Mehta, Neil; Heimbach, Julie K.; Dawson, Laura A.; Jou, Janice H.; Kulik, Agopian, Vatche Marrero, Jorge Mendiratta-Lala, Mishal; Brown, Daniel B.; Rilling, William S.; Goyal, Lipika; Wei, Alice C.; Taddei, Tamar H. Author Information

Language: Английский

Citations

713
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) DOI Creative Commons
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong

et al.

Journal of Hepatology, Journal Year: 2024, Volume and Issue: 81(3), P. 492 - 542

Published: June 7, 2024

Language: Английский

Citations

314
MASLD: a systemic metabolic disorder with cardiovascular and malignant complications DOI Open Access
Giovanni Targher, Christopher D. Byrne, Herbert Tilg

et al.

Gut, Journal Year: 2024, Volume and Issue: unknown, P. gutjnl - 330595

Published: Jan. 16, 2024

Non-alcoholic fatty liver disease (NAFLD) has rapidly become the most common chronic globally and is currently estimated to affect up 38% of global adult population. NAFLD a multisystem where systemic insulin resistance related metabolic dysfunction play pathogenic role in development its relevant liver-related morbidities (cirrhosis, failure hepatocellular carcinoma) extrahepatic complications, such as cardiovascular (CVD), type 2 diabetes mellitus, kidney disease, certain types cancers. In 2023, three large multinational associations proposed that dysfunction-associated steatotic (MASLD) should replace term NAFLD; name chosen non-alcoholic steatohepatitis was (MASH). Emerging epidemiological evidence suggests an excellent concordance rate between MASLD definitions—that is, ~99% individuals with meet criteria. this narrative review, we provide overview literature on (a) recent data risk developing CVD malignant (b) underlying mechanisms by which (and factors strongly linked MASLD) may increase these complications (c) diagnosis assessment potential treatments reduce people or MASH.

Language: Английский

Citations

258
Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment DOI
Josep M. Llovet, Catherine E. Willoughby, Amit G. Singal

et al.

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2023, Volume and Issue: 20(8), P. 487 - 503

Published: March 17, 2023

Language: Английский

Citations

191
The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines: 2022 update DOI Open Access
Ningyuan Wen,

Yulong Cai,

Fu‐Yu Li

et al.

BioScience Trends, Journal Year: 2022, Volume and Issue: 16(1), P. 20 - 30

Published: Feb. 23, 2022

Hepatocellular carcinoma (HCC) is the fifth most common malignancy and second leading cause of cancer-related mortality worldwide. This review an updated version that summarizes comprehensive guidelines published from January 2001 to 2022 worldwide with a focus on clinical management HCC. The electronic databases MEDLINE, Chinese SinoMed, Japanese CiNii were systematically searched. A total 22 characteristic for HCC ultimately included, including 1 international guideline, 11 Asia, 5 Europe, 4 America, Australia. If in multiple versions, recent update was surveillance, diagnosis, treatment compared. composition recommendations current varied, so these regrouped diagnostic algorithms summarized graphically provide latest information clinicians. criteria grouped into 2 categories: "Size-based pathway" "Non-size-based pathway". according different algorithms, mainstream options reviewed. Findings comparison might help target concentrate efforts improve However, further studies are needed outcomes More straightforward or refined would guide doctors make better decisions future.

Language: Английский

Citations

137
Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma DOI Creative Commons
Qian Song, Xiang Zhang, Weixin Liu

et al.

Journal of Hepatology, Journal Year: 2023, Volume and Issue: 79(6), P. 1352 - 1365

Published: July 17, 2023

Recent studies have highlighted the role of gut microbiota and their metabolites in non-alcoholic fatty liver disease-associated hepatocellular carcinoma (NAFLD-HCC). We aimed to identify specific beneficial bacterial species that could be used prophylactically prevent NAFLD-HCC.

Language: Английский

Citations

96
Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology DOI
Daniel Q. Huang, Amit G. Singal, Fasiha Kanwal

et al.

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2023, Volume and Issue: 20(12), P. 797 - 809

Published: Aug. 3, 2023

Language: Английский

Citations

86
Exposure to perfluoroalkyl substances and risk of hepatocellular carcinoma in a multiethnic cohort DOI
Jesse A. Goodrich, Douglas I. Walker, Xiangping Lin

et al.

JHEP Reports, Journal Year: 2022, Volume and Issue: 4(10), P. 100550 - 100550

Published: Aug. 8, 2022

Language: Английский

Citations

78
EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) DOI Creative Commons
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong

et al.

Obesity Facts, Journal Year: 2024, Volume and Issue: 17(4), P. 374 - 444

Published: Jan. 1, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed non-alcoholic fatty (NAFLD), is defined as (SLD) in the presence of one or more cardiometabolic risk factor(s) and absence harmful alcohol intake. The spectrum MASLD includes steatosis, metabolic steatohepatitis (MASH, NASH), fibrosis, cirrhosis MASH-related hepatocellular carcinoma (HCC). This joint EASL-EASD-EASO guideline provides an update on definitions, prevention, screening, diagnosis treatment for MASLD. Case-finding strategies with using non-invasive tests, should be applied individuals factors, abnormal enzymes, and/or radiological signs hepatic particularly type 2 diabetes (T2D) obesity additional factor(s). A stepwise approach blood-based scores (such FIB-4) and, sequentially, imaging techniques transient elastography) suitable to rule-out/in advanced which predictive liver-related outcomes. In adults MASLD, lifestyle modification - including weight loss, dietary changes, physical exercise discouraging consumption well optimal management comorbidities use incretin-based therapies (e.g. semaglutide, tirzepatide) T2D obesity, if indicated advised. Bariatric surgery also option obesity. If locally approved dependent label, non-cirrhotic MASH significant fibrosis (stage ≥2) considered a MASH-targeted resmetirom, demonstrated histological effectiveness acceptable safety tolerability profile. No pharmacotherapy can currently recommended cirrhotic stage. Management adaptations drugs, nutritional counselling, surveillance portal hypertension HCC, transplantation decompensated cirrhosis.

Language: Английский

Citations

59
Molecular mechanisms in MASLD/MASH-related HCC DOI
Xiaobo Wang, Liang Zhang, Bingning Dong

et al.

Hepatology, Journal Year: 2024, Volume and Issue: unknown

Published: Feb. 13, 2024

Liver cancer is the third leading cause of cancer-related deaths and ranks as sixth most prevalent type globally. NAFLD or metabolic dysfunction-associated steatotic liver disease, its more severe manifestation, NASH steatohepatitis (MASH), pose a significant global health concern, affecting approximately 20%-25% population. The increased prevalence disease MASH parallel to increasing rates obesity-associated diseases, including 2 diabetes, insulin resistance, fatty diseases. can progress MASH-related HCC (MASH-HCC) in about 2% cases each year, influenced by various factors such genetic mutations, carcinogen exposure, immune microenvironment, microbiome. MASH-HCC exhibits distinct molecular characteristics compared other causes affects both men women equally. management early intermediate-stage typically involves surgery locoregional therapies, while advanced treated with systemic anti-angiogenic therapies checkpoint inhibitors. In this comprehensive review, we consolidate previous research findings also providing current insights into intricate processes underlying development. We delve MASH-HCC-associated variations somatic progression models, multiomics analysis, immunological microenvironmental impacts, discuss targeted/combined overcome evasion biomarkers recognize treatment responders. By furthering our comprehension mechanisms MASH-HCC, goal catalyze advancement potent strategies, ultimately enhanced patient outcomes.

Language: Английский

Citations

43